Treatment of Status Epilepticus with Ketamine, Are we There yet?

CNS Neuroscience and Therapeutics

Volumn 19, Issue 6, 2013, Pages 411-427

  Dorandeu, Frederic ^a,b   Dhote, Franck ^a   Barbier, Laure ^a   Baccus, Benjamin ^a   Testylier, Guy ^a  

^a CENTRE DE RECHERCHES   (France)

^b Ecole du Val de Grace   (France)

Author keywords

Ketamine; Neuroprotection; NMDA antagonists; Status epilepticus

Indexed keywords

ATROPINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; DIAZEPAM; DIZOCILPINE; ETIRACETAM; ETOMIDATE; FLUNARIZINE; FOSPHENYTOIN SODIUM; GLUTAMATE RECEPTOR ANTAGONIST; HARKOSERIDE; KETAMINE; LORAZEPAM; MEMANTINE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; ORGANOPHOSPHORUS COMPOUND; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PROPOFOL; THIOPENTAL; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

AIRWAY OBSTRUCTION; AMYGDALOID NUCLEUS; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BRAIN DAMAGE; BRAIN METABOLISM; CARDIOVASCULAR EFFECT; CATECHOLAMINE BLOOD LEVEL; CELL DEATH; CENTRAL VENOUS PRESSURE; DRUG EFFICACY; ELECTROSTIMULATION; EPILEPTIC STATE; EPILEPTOGENESIS; GABAERGIC TRANSMISSION; HEART OUTPUT; HEART RATE; HIPPOCAMPUS; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; INTRACRANIAL HYPERTENSION; LOW DRUG DOSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PNEUMONIA; PYRIFORM CORTEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; SEIZURE; THALAMUS; THERAPY; TREATMENT DURATION;

ANALGESICS; ANIMALS; HUMANS; KETAMINE; POISONS; RECEPTORS, N-METHYL-D-ASPARTATE; STATUS EPILEPTICUS;

EID: 84878129430     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12096     Document Type: Review

References (257)

1. Bleck TP. Status epilepticus and the use of continuous EEG monitoring in the intensive care unit. Continuum (Minneap Minn) 2012;18:560-578.
2. Murdoch D. Mechanisms of status epilepticus: an evidence-based review. Curr Opin Neurol 2007;20:213-216.
3. Rosenow F, Knake S. Recent and future advances in the treatment of status epilepticus. Ther Adv Neurol Disord 2008;1:33-42.
4. Kalviainen R. Status epilepticus treatment guidelines. Epilepsia 2007;48(Suppl 8):99-102.
5. Knake S, Hamer HM, Rosenow F. Status epilepticus: a critical review. Epilepsy Behav 2009;15:10-14.
6. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006;5:246-256.
7. Wasterlain CG, Chen JW. Definition and classification of status epilepticus. In: Wasterlain CG, Treiman DM, editors. Status epilepticus Mechanisms and management. Cambridge, Massachusetts: The MIT Press, 2006; 11-16.
8. Treiman DM. Generalized convulsive status epilepticus. In: Wasterlain CG, Treiman DM, editors. Status epilepticus Mechanisms and management. Cambridge, Massachusetts: The MIT Press, 2006; 55-68.
9. van Rijckevorsel K, Boon P, Hauman H, et al. Standards of care for adults with convulsive status epilepticus: Belgian consensus recommendations. Acta Neurol Belg 2005;105:111-118.
10. Outin H, Blanc T, Vinatier I, Le groupe d'experts. Prise en charge en situation d'urgence et en réanimation des états de mal épileptiques de l'adulte et de l'enfant (nouveau-né exclu). Recommandations formalisées d'experts sous l'égide de la Société de réanimation de langue française. Réanimation 2009;18:4-12.
11. van Rijckevorsel K, Boon P, Hauman H, et al. Standards of care for non-convulsive status epilepticus: Belgian consensus recommendations. Acta Neurol Belg 2006;106:117-124.
12. Olney JW, Collins RC, Sloviter RS. Excitotoxic mechanisms of epileptic brain damage. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ, editors. Adv Neurol. New York: Raven Press, 1986; 857-877.
13. Gardoni F, Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006;545:2-10.
14. Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005;179:4-29.
15. Kohl BK, Dannhardt G. The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr Med Chem 2001;8:1275-1289.
16. Stone TW, Addae JI. The pharmacological manipulation of glutamate receptors and neuroprotection. Eur J Pharmacol 2002;447:285-296.
17. Pazdernik TL, Emerson MR, Cross R, Nelson SR, Samson FE. Soman-induced seizures: limbic activity, oxidative stress and neuroprotective proteins. J Appl Toxicol 2001;21(Suppl 1):S87-S94.
18. Dhote F, Peinnequin A, Carpentier P, et al. Prolonged inflammatory gene response following soman-induced seizures in mice. Toxicology 2007;238:166-176.
19. Williams AJ, Berti R, Yao C, et al. Central neuro-inflammatory gene response following soman exposure in the rat. Neurosci Lett 2003;349:147-150.
20. Svensson I, Waara L, Johansson L, Bucht A, Cassel G. Soman-induced interleukin-1 beta mRNA and protein in rat brain. Neurotoxicology 2001;22:355-362.
21. Ormandy GC, Jope RS, Snead OCD. Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats. Exp Neurol 1989;106:172-180.
22. Johnson KM, Jones SM. Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 1990;30:707-750.
23. Clifford DB, Olney JW, Benz AM, Fuller TA, Zorumski CF. Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990;31:382-390.
24. Walton NY, Treiman DM. Motor and electroencephalographic response of refractory experimental status epilepticus in rats to treatment with MK-801, diazepam, or MK-801 plus diazepam. Brain Res 1991;553:97-104.
25. Sparenborg S, Brennecke LH, Jaax NK, Braitman DJ. Dizocilpine (MK-801) arrests status epilepticus and prevents brain damage induced by soman [published erratum appears in Neuropharmacology 1993 Mar;32(3):313]. Neuropharmacology 1992;31:357-368.
26. Braitman DJ, Sparenborg S. MK-801 protects against seizures induced by the cholinesterase inhibitor soman. Brain Res Bull 1989;23:145-148.
27. Shih TM. Anticonvulsant effects of diazepam and MK-801 in soman poisoning. Epilepsy Res 1990;7:105-116.
28. Shih TM, Koviak TA, Capacio BR. Anticonvulsants for poisoning by the organophosphorus compound soman: pharmacological mechanisms. Neurosci Biobehav Rev 1991;15:349-362.
29. McDonough JH Jr, Shih TM. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 1997;21:559-579.
30. Sparenborg S, Brenneche LH, Braitman DJ. Neurons are rescued from soman-induced brain damage by the neuroprotectant MK-801 after two hours of status epilepticus (conference proceedings). Biosci Med Def Rev; 1991; Baltimore, MD.
31. McDonough JH Jr, Shih TM. Pharmacological modulation of soman-induced seizures. Neurosci Biobehav Rev 1993;17:203-215.
32. Blanchet G, Carpentier P, Lallement G, Tarricone A, Sentenac H, Kamenka J-K. Anticonvulsant effects of N-[1-(2-thienyl) cyclohexyl]-piperidine (TCP) in soman poisoning. In: Kamenka J-M, Domino EF (eds). Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? Ann Arbor (MI): NPP Books, 1992; 831-840.
33. Carpentier P, Foquin Tarricone A, Bodjarian N, et al. Anticonvulsant and antilethal effects of the phencyclidine derivative TCP in soman poisoning. Neurotoxicology 1994;15:837-851.
34. Carpentier P, Foquin A, Kamenka JM, et al. Effects of thienylphencyclidine (TCP) on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neurotoxicity. Neurotoxicology 2001;22:13-28.
35. de Groot DMG, Bierman EPB, Bruijnzeel PLB, et al. Beneficial effects of TCP on soman intoxication in guinea pigs: Seizures, brain damage and learning behaviour. J Appl Toxicol 2001;21:S57-S65.
36. Dorandeu F, Carpentier P, Baille V, et al. Field treatment of soman-induced self-sustaining status epilepticus. Are ketamine and other NMDA antagonists the only options? In: Weissman BA, Raveh L, editors. The Neurochemical Consequences of Organophosphate Poisoning in the CNS. Kerala, India: Transworld Research Network, 2010; 149-183.
37. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 1989;167:127-135.
38. Kemp JA, Foster AC, Wong EHF. Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 1987;10:294-298.
39. Burns RS, Lerner SE. Perspectives: acute phencyclidine intoxication. Clin Toxicol 1976;9:477-501.
40. Filliat P, Blanchet G. Effects of TCP on spatial memory: comparison with MK-801. Pharmacol Biochem Behav 1995;51:429-434.
41. Hirbec H, Gaviria M, Vignon J. Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. CNS Drug Rev 2001;7:172-198.
42. Lallement G, Mestries JC, Privat A, et al. GK 11: promising additional neuroprotective therapy for organophosphate poisoning. Neurotoxicology 1997;18:851-856.
43. Lallement G, Clarençon D, Masqueliez C, et al. Nerve agent poisoning in primates: antilethal, anti-epileptic and neuroprotective effects of GK-11. Arch Toxicol 1998;72:84-92.
44. Lallement G, Clarençon D, Galonnier M, Baubichon D, Burckhart MF, Peoc'h M. Acute soman poisoning in primates neither pretreated nor receiving immediate therapy: value of gacyclidine (GK-11) in delayed medical support. Arch Toxicol 1999;73:115-122.
45. Bhagat YA, Obenaus A, Hamilton MG, Mikler J, Kendall EJ. Neuroprotection from soman-induced seizures in the rodent: evaluation with diffusion- and T2-weighted magnetic resonance imaging. Neurotoxicology 2005;26:1001-1013.
46. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010;113:678-684.
47. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998;87:1186-1193.
48. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol 2008;182:313-333.
49. Mion G, Villevieille T. Ketamine pharmacology: an update. CNS Neurosci Ther 2013; 19:370-380.
50. Gofrit ON, Leibovici D, Shemer J, Henig A, Shapira SC. Ketamine in the field: the use of ketamine for induction of anaesthesia before intubation in injured patients in the field. Injury 1997;28:41-43.
51. Annetta MG, Iemma D, Garisto C, Tafani C, Proietti R. Ketamine: new indications for an old drug. Curr Drug Targets 2005;6:789-794.
52. Mion G, Petitjeans F, Tourtier J-P, Villevieille T, Tortosa J-C. Kétamine et fonction respiratoire. In: Mion G, editor. Ketamine. Paris: Arnette, 2003; 121-140.
53. Cromhout A. Ketamine: its use in the emergency department. Emerg Med (Fremantle) 2003;15:155-159.
54. Marland S, Ellerton J, Andolfatto G, et al. Ketamine - use in anesthesia. CNS Neurosci Ther 2013; 19:381-389.
55. Restall J, Thompson MC, Johnston IG, Fenton TC. Anaesthesia in the field. Spontaneous ventilation - a new technique. Anaesthesia 1990;45:965-968.
56. Restall J, Tully AM, Ward PJ, Kidd AG. Total intravenous anaesthesia for military surgery. A technique using ketamine, midazolam and vecuronium. Anaesthesia 1988;43:46-49.
57. Craven R. Ketamine. Anaesthesia 2007; 62 Suppl 1: 48-53.
58. Saby RC, Mardelle V, Gil C, Petrognani R, Mion G, Carpentier JP. [Ketamine: drug facts, uses in anesthesia, and new applications for analgesia]. Med Trop (March) 2006;66:125-129.
59. Riou B. Effets cardiovasculaires de la kétamine. In: Mion G, editor. Ketamine. Paris: Arnette, 2003; 109-120.
60. Ceber M, Salihoglu T. Ketamine may be the first choice for anesthesia in burn patients. J Burn Care Res 2006;27:760-762.
61. Svenson JE, Abernathy MK. Ketamine for prehospital use: new look at an old drug. Am J Emerg Med 2007;25:977-980.
62. Ben-Ari A, Lewis MC, Davidson E. Chronic administration of ketamine for analgesia. J Pain Palliat Care Pharmacother 2007;21:7-14.
63. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006;25:CD004603.
64. Persson J. Ketamine in pain management. CNS Neurosci Ther 2013; 19:396-402.
65. Salvadore G, Singh J. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther 2013; 19:428-436.
66. Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003;69:23-28.
67. Corazza O, Assi S, Schifano F. From "special K" to "special M": the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 2013; 19:454-460.
68. Spigelman I. Physiologic mechanisms of inhibition and status epilepticus. In: Wasterlain CG, Treiman DM, editors. Status epilepticus Mechanisms and management. Cambridge, Massachusetts: The MIT Press, 2006; 281-293.
69. Wasterlain CG, Chen JW. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 2008;49(Suppl 9):63-73.
70. Mazarati A, Liu H, Naylor D, et al. Self-sustaining status epilepticus. In: Wasterlain CG, Treiman DM, editors. Status epilepticus Mechanisms and management. Cambridge, Massachusetts: The MIT Press, 2006; 209-228.
71. Simon RP. Physiologic responses to status epilepticus. In: Wasterlain CG, Treiman DM, editors. Status epilepticus Mechanisms and management. Cambridge, Massachusetts: The MIT Press, 2006; 149-161.
72. Perks A, Cheema S, Mohanraj R. Anaesthesia and epilepsy. Br J Anaesth 2012;108:562-571.
73. Faught E, DeGiorgio CM. Generalized convulsive status epilepticus: principles of treatment. In: Wasterlain CG, Treiman DM, editors. Status epilepticus Mechanisms and management. Cambridge, Massachusetts: The MIT Press, 2006; 481-491.
74. Newmark J. Nerve agents. Neurologist 2007; 13: 20-32.
75. Carpentier P, Foquin A, Rondouin G, Lerner Natoli M, de Groot DMG, Lallement G. Effects of atropine sulphate on seizure activity and brain damage produced by soman in guinea-pigs: ECoG correlates of neuropathology. Neurotoxicology 2000;21:521-540.
76. Carpentier P, Delamanche IS, Le-Bert M, Blanchet G, Bouchaud C. Seizure-related opening of the blood-brain barrier induced by soman: possible correlation with the acute neuropathology observed in poisoned rats. Neurotoxicology 1990;11:493-508.
77. Lemercier G, Carpentier P, Sentenac-Roumanou H, Morelis P. Histological and histochemical changes in the central nervous system of the rat poisoned by an irreversible anticholinesterase organophosphorus compound. Acta Neuropathol Berl 1983;61:123-129.
78. Petras JM. Neurology and neuropathology of Soman-induced brain injury: an overview. J Exp Anal Behav 1994;61:319-329.
79. Myhrer T, Andersen JM, Nguyen NH, Aas P. Soman-induced convulsions in rats terminated with pharmacological agents after 45 min: neuropathology and cognitive performance. Neurotoxicology 2005;26:39-48.
80. Filliat P, Coubard S, Pierard C, et al. Long-term behavioral consequences of soman poisoning in mice. Neurotoxicology 2007;28:508-519.
81. Dorandeu F, Carpentier P, Baubichon D, et al. Efficacy of the ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res 2005;1051:164-175.
82. de Araujo Furtado M, Lumley LA, Robison C, Tong LC, Lichtenstein S, Yourick DL. Spontaneous recurrent seizures after status epilepticus induced by soman in Sprague-Dawley rats. Epilepsia 2010;51:1503-1510.
83. de Araujo Furtado M, Rossetti F, Chanda S, Yourick D. Exposure to nerve agents: From status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy. Neurotoxicology 2012;33:1476-1490.
84. Carpentier P, Testylier G, Baille V, et al. Soman-Induced Seizures and Related Brain Damage: How to Treat Seizures and Assess Their Effects Non-Invasively? J Med Chem Biol Radiol Def 2008;6:1-16.
85. Weissman BA, Raveh L. Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. Toxicol Appl Pharmacol 2008;232:351-358.
86. Shih T-M, McDonough JH. Neurochemical mechanisms in soman-induced seizures. J Appl Toxicol 1997;17:255-264.
87. Filbert M, Levine E, Ballough G. Neuroprotection for nerve agent-induced brain damage by blocking delayed calcium overload: a review. J Med Chem Biol Radiol Def 2005;3:1-21.
88. Raveh L, Chapman S, Cohen G, et al. The involvement of the NMDA receptor complex in the protective effect of anticholinergic drugs against soman poisoning. Neurotoxicology 1999;20:551-559.
89. Raveh L, Weissman BA, Cohen G, et al. Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology 2002;23:7-17.
90. Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol 2008;38:377-390.
91. Mnatsakanyan L, Chung JM, Tsimerinov EI, Eliashiv DS. Intravenous Lacosamide in refractory nonconvulsive status epilepticus. Seizure 2012;21:198-201.
92. Jaques L, Rossetti AO. Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis. Epilepsy Behav 2012;24:70-73.
93. Koplovitz I, Schulz S, Shutz M, et al. Combination anticonvulsant treatment of soman-induced seizures. J Appl Toxicol 2001;21(Suppl 1):S53-S55.
94. Myhrer T, Skymoen LR, Aas P. Pharmacological agents, hippocampal EEG, and anticonvulsant effects on soman-induced seizures in rats. Neurotoxicology 2003;24:357-367.
95. Myhrer T, Enger S, Aas P. Efficacy of immediate and subsequent therapies against soman-induced seizures and lethality in rats. Basic Clin Pharmacol Toxicol 2006;98:184-191.
96. Myhrer T, Enger S, Jonassen M, Aas P. Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats. Neurotoxicology 2011;32:923-930.
97. Ho LK, Loo HK, Loke WK. Neuroprotective combination of clonidine-atropine for established and refractory status epilepticus arising from lethal soman exposure (conference proceedings). 5th SISPAT conferences; 2006; Singapore.
98. Kalviainen R, Eriksson K, Parviainen I. Refractory generalised convulsive status epilepticus: a guide to treatment. CNS Drugs 2005;19:759-768.
99. Manno EM. New management strategies in the treatment of status epilepticus. Mayo Clin Proc 2003;78:508-518.
100. Chung SS, Wang NC, Treiman DM. Comparative efficacy and safety of antiepileptic drugs for the treatment of status epilepticus. J Pharm Pract 2007;20:137-146.
101. Raj D, Gulati S, Lodha R. Status epilepticus. Indian J Pediatr 2011;78:219-226.
102. Gilat E, Goldman M, Lahat E, et al. Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig. Arch Toxicol 2003;77:167-172.
103. McDonough JH, Van Shura KE, LaMont JC, McMonagle JD, Shih TM. Comparison of the intramuscular, intranasal or sublingual routes of midazolam administration for the control of soman-induced seizures. Basic Clin Pharmacol Toxicol 2009;104:27-34.
104. Eisenkraft A, Gilat E, Chapman S, Baranes S, Egoz I, Levy A. Efficacy of the bone injection gun in the treatment of organophosphate poisoning. Biopharm Drug Dispos 2007;28:145-150.
105. McDonough JH, Benjamin A, McMonagle JD, Rowland T, Shih TM. Effects of fosphenytoin on nerve agent-induced status epilepticus. Drug Chem Toxicol 2004;27:27-39.
106. Shih TM, McDonough JH, Koplovitz I. Anticonvulsants for soman-induced seizure activity. J Biomed Sci 1999;6:86-96.
107. Peterson S. Treatment strategies for the NMDA component of organophosphorus convulsions. US Army Medical Research and Material Command University of New Mexico Health Science Center2005. Report No.: DAMD17-01-1-0794 - US Army Medical Research and Material Command.
108. Fernandez A, Claassen J. Refractory status epilepticus. Curr Opin Crit Care 2012;18:127-131.
109. Shorvon S, Ferlisi M. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 2012;135:2314-2328.
110. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;134:2802-2818.
111. Stein AG, Fisher RS. Other pharmacologic therapy for refractory status epilepticus. In: Wasterlain CG, Treiman DM, editors. Status epilepticus Mechanisms and management. Cambridge, Massachusetts: The MIT Press, 2006; 569-587.
112. Manocha A, Sharma KK, Mediratta PK. Possible mechanism of anticonvulsant effect of ketamine in mice. Indian J Exp Biol 2001;39:1002-1008.
113. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000;42:117-122.
114. Khanna N, Bhalla S. Role of ketamine in convulsions. Indian J Med Sci 1999;53:475-480.
115. Mazarati AM, Wasterlain CG. N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 1999;265:187-190.
116. Bertram EH, Lothman EW. NMDA receptor antagonists and limbic status epilepticus: a comparison with standard anticonvulsants. Epilepsy Res 1990;5:177-184.
117. Mikolasova R, Velisek L, Vorlicek J, Mares P. Developmental changes of ketamine action against epileptic after discharges induced by hippocampal stimulation in rats. Brain Res Dev Brain Res 1994;81:105-112.
118. Gorter JA, van Vliet EA, Aronica E, Lopes da Silva FH. Long-lasting increased excitability differs in dentate gyrus vs. CA1 in freely moving chronic epileptic rats after electrically induced status epilepticus. Hippocampus 2002;12:311-324.
119. Borowicz KK, Czuczwar SJ. Effects of etomidate, ketamine or propofol, and their combinations with conventional antiepileptic drugs on amygdala-kindled convulsions in rats. Neuropharmacology 2003;45:315-324.
120. Borowicz KK, Luszczki J, Czuczwar SJ. Interactions between non-barbiturate injectable anesthetics and conventional antiepileptic drugs in the maximal electroshock test in mice-an isobolographic analysis. Eur Neuropsychopharmacol 2004;14:163-172.
121. De Sarro GB, De Sarro A. Anticonvulsant properties of non-competitive antagonists of the N- methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene. Neuropharmacology 1993;32:51-58.
122. Arfel G, De Lavarde M, De Pommery J, De Pommery H. [Action of ketamine of paroxysmal discharges provoked by air emboli in the baboon Papio papio]. Electroencephalogr Clin Neurophysiol 1976;41:357-366.
123. Gondran M, Eckeli AL, Migues PV, Gabilan NH, Rodrigues AL. The crude extract from the sea anemone, Bunodosoma caissarum elicits convulsions in mice: possible involvement of the glutamatergic system. Toxicon 2002;40:1667-1674.
124. Cook LL. Ventricular enlargement and the lithium/pilocarpine seizure model: possible explanation for agonistic behaviour. Int J Neurosci 2000;100:117-123.
125. Mudo G, Jiang XH, Timmusk T, Bindoni M, Belluardo N. Change in neurotrophins and their receptor mRNAs in the rat forebrain after status epilepticus induced by pilocarpine. Epilepsia 1996;37:198-207.
126. Lallement G, Dorandeu F, Filliat P, Carpentier P, Baille V, Blanchet G. Medical management of organophosphate-induced seizures. J Physiol - Paris 1998;92:369-373.
127. Loss CM, Cordova SD, de Oliveira DL. Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. Brain Res 2012;1474:110-117.
128. Stewart LS, Persinger MA. Ketamine Prevents Learning Impairment When Administered Immediately after Status Epilepticus Onset. Epilepsy Behav 2001;2:585-591.
129. Santi SA, Cook LL, Persinger MA, O'Connor RP. Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents. Int J Neurosci 2001;107:63-75.
130. Persinger MA, St-Pierre LS. The brain matrix and multifocal brain damage following a single injection of ketamine in young adult rats: conspicuous changes in old age. Percept Mot Skills 2002;95:897-900.
131. McKay BE, Persinger MA. Normal spatial and contextual learning for ketamine-treated rats in the pilocarpine epilepsy model. Pharmacol Biochem Behav 2004;78:111-119.
132. Fournier NM, Persinger MA. The neuromatrix and the epileptic brain: behavioral and learning preservation in limbic epileptic rats treated with ketamine but not acepromazine. Epilepsy Behav 2004;5:119-127.
133. Vermoesen K, Smolders I, Massie A, Michotte Y, Clinckers R. The control of kainic acid-induced status epilepticus. Epilepsy Res 2010;90:164-166.
134. Cunha AO, Mortari MR, Liberato JL, dos Santos WF. Neuroprotective effects of diazepam, carbamazepine, phenytoin and ketamine after pilocarpine-induced status epilepticus. Basic Clin Pharmacol Toxicol 2009;104:470-477.
135. Fujikawa DG. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 1995;36:186-195.
136. Hort J, Brozek G, Mares P, Langmeier M, Komarek V. Cognitive functions after pilocarpine-induced status epilepticus: changes during silent period precede appearance of spontaneous recurrent seizures. Epilepsia 1999;40:1177-1183.
137. St-Pierre LS, Persinger MA. Extreme obesity in female rats following prepuberal induction of lithium-pilocarpine seizures and a single injection of acepromazine. Epilepsy Behav 2005;7:411-418.
138. St-Pierre LS, Bubenik GA, Parker GH, Persinger MA. Insidious weight gain in prepubertal seized rats treated with an atypical neuroleptic: the role of food consumption, fluid consumption, and spontaneous ambulatory activity. Epilepsy Behav 2009;14:288-292.
139. George KR, Rico T, St-Pierre LS, et al. Large Differences in Blood Measures, Tissue Weights and Focal Areas of Damage One Year After Post-Seizure Treatment with Acepromazine or Ketamine. Epilepsy Behav 2009;15:98-105.
140. Vaillancourt LN, Persinger MA. Normalization of spatial learning despite brain damage in rats receiving ketamine after seizure-induction: evidence for the neuromatrix. Psychol Rep 2001;88:102-110.
141. Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia 2008;49:248-255.
142. Pereira MB, Freitas RL, Assis MA, et al. Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats. Neurosci Lett 2007;419:253-257.
143. Freitas RM, Sousa FC, Viana GS, Fonteles MM. Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus. Neurosci Lett 2006;408:79-83.
144. Sroubek J, Hort J, Komarek V, Langmeier M, Brozek G. Acquisition and retrieval of conditioned taste aversion is impaired by brain damage caused by two hours of pilocarpine-induced status epilepticus. Physiol Res 2001;50:609-617.
145. Dorandeu F, Baille V, Mikler J, et al. Protective effects of S(+) ketamine and atropine against lethality and brain damage during soman-induced status epilepticus in guinea-pigs. Toxicology 2007;234:185-193.
146. Dhote F, Carpentier P, Barbier L, et al. Combinations of ketamine and atropine are neuroprotective and reduce neuroinflammation after a toxic status epilepticus in mice. Toxicol Appl Pharmacol 2012;259:195-209.
147. Fauvelle F, Carpentier P, Dorandeu F, Foquin A, Testylier G. Prediction of neuroprotective treatment efficiency using a HRMAS NMR-based statistical model of refractory status epilepticus on mouse: a metabolomic approach supported by histology. J Proteome Res 2012;11:3782-3795.
148. Stafstrom CE, Sasaki-Adams DM. NMDA-induced seizures in developing rats cause long-term learning impairment and increased seizure susceptibility. Epilepsy Res 2003;53:129-137.
149. Bennett DA, Bernard PS, Amrick CL. A comparison of PCP-like compounds for NMDA antagonism in two in vivo models. Life Sci 1988;42:447-454.
150. Sharma AC, Thorat SN, Nayar U, Kulkarni SK. Dizocilpine, ketamine and ethanol reverse NMDA-induced EEG changes and convulsions in rats and mice. Indian J Physiol Pharmacol 1991;35:111-116.
151. Palmer GC, Harris EW, Ray R, Stagnitto ML, Schmiesing RJ. Classification of compounds for prevention of NMDLA-induced seizures/mortality, or maximal electroshock and pentylenetetrazol seizures in mice and antagonism of MK801 binding in vitro. Arch Int Pharmacodyn Ther 1992;317:16-34.
152. Sofia RD, Gordon R, Gels M, Diamantis W. Comparative effects of felbamate and other compounds on N-methyl-D- aspartic acid-induced convulsions and lethality in mice. Pharmacol Res 1994;29:139-144.
153. Lees GJ. Influence of ketamine on the neuronal death caused by NMDA in the rat hippocampus. Neuropharmacology 1995;34:411-417.
154. Clifford DB, Zorumski CF, Olney JW. Ketamine and MK-801 prevent degeneration of thalamic neurons induced by focal cortical seizures. Exp Neurol 1989;105:272-279.
155. Wardley-Smith B, Little HJ, Halsey MJ. Lack of correlation between the anaesthetic and anti-convulsant potencies of althesin, ketamine and methohexitone. Br J Anaesth 1988;60:140-145.
156. Veliskova J, Velisek L, Mares P, Rokyta R. Ketamine suppresses both bicuculline- and picrotoxin-induced generalized tonic-clonic seizures during ontogenesis. Pharmacol Biochem Behav 1990;37:667-674.
157. Irifune M, Sato T, Kamata Y, Nishikawa T, Dohi T, Kawahara M. Evidence for GABA(A) receptor agonistic properties of ketamine: convulsive and anesthetic behavioral models in mice. Anesth Analg 2000;91:230-236.
158. Celesia GG, Chen RC. Effects of ketamine on EEG activity in cats and monkeys. Electroencephalogr Clin Neurophysiol 1974;37:345-353.
159. Sagratella S, Niglio T, Scotti de Carolis A. An investigation on the mechanism of anticonvulsant action of ketamine and phencyclidine on convulsions due to cortical application of penicillin in rabbits. Pharmacol Res Commun 1985;17:773-786.
160. Myslobodsky MS, Golovchinsky V, Mintz M. Ketamine: convulsant or anti-convulsant? Pharmacol Biochem Behav 1981;14:27-33.
161. Ghasemi M, Shafaroodi H, Nazarbeiki S, et al. Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice. Epilepsy Behav 2010;18:171-178.
162. Velisek L, Mikolasova R, Blankova-Vankova S, Mares P. Effects of ketamine on metrazol-induced seizures during ontogenesis in rats. Pharmacol Biochem Behav 1989;32:405-410.
163. Taberner PV. The anticonvulsant activity of ketamine against seizures induced by pentylenetetrazol and mercaptopropionic acid. Eur J Pharmacol 1976;39:305-311.
164. Kofke WA, Towfighi J, Garman RH, Graybeal JM, Housman C, Hawkins RA. Effect of anesthetics on neuropathologic sequelae of status epilepticus in rats. Anesth Analg 1993;77:330-337.
165. Guler G, Erdogan F, Golgeli A, Akin A, Boyaci A. Ketamine reduces lidocaine-induced seizures in mice. Int J Neurosci 2005;115:1239-1244.
166. Szakacs R, Weiczner R, Mihaly A, Krisztin-Peva B, Zador Z, Zador E. Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. Brain Res Bull 2003;59:485-493.
167. Shakarjian MP, Veliskova J, Stanton PK, Velisek L. Differential antagonism of tetramethylene disulfotetramine-induced seizures by agents acting at NMDA and GABA(A) receptors. Toxicol Appl Pharmacol 2012;265:113-121.
168. Pan JC, Pei YQ, An L, Lai L, D'Hooge R, De Deyn PP. Epileptiform activity and hippocampal damage produced by intrahippocampal injection of guanidinosuccinic acid in rat. Neurosci Lett 1996;209:121-124.
169. Dorandeu F, Barbier L, Dhote F, Testylier G, Carpentier P. Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of current data and perspectives. Chem Biol Interact 2012; doi: 10.1016/j.cbi.2012.09.013.
170. Hilmas CJ, Williams PT. Novel Mechanism to Explain Ketamine Efficacy Against Nerve Agent-Induced Seizures (conference proceedings). Defence against the Effects of Chemical Hazards: Toxicology, Diagnosis and Medical Countermeasures. Edimburgh: Meeting Proceedings Available from: http://www.rto.nato.int. RTO-MP-HFM-149, Paper 29. Neuilly-sur-Seine, France: RTO, 2007.
171. Wasterlain CG, Fujikawa DG, Penix L, Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993;34(Suppl 1):37-53.
172. Houser CR. Neuronal loss and synaptic reorganization in temporal lobe epilepsy. Adv Neurol 1999;79:743-761.
173. Brandt C, Potschka H, Loscher W, Ebert U. N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy. Neuroscience 2003;118:727-740.
174. Holtkamp M, Meierkord H. Anticonvulsant, antiepileptogenic, and antiictogenic pharmacostrategies. Cell Mol Life Sci 2007;64:2023-2041.
175. Pernot F, Carpentier P, Baille V, et al. Intrahippocampal cholinesterase inhibition induces epileptogenesis in mice without evidence of neurodegenerative events. Neuroscience 2009;162:1351-1365.
176. de Kock M, Loix S, Lavand'homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther 2013;19:403-410.
177. Flecknell PA. Laboratory animal anaesthesia. An introduction for research workers and technicians. London: Academic Press, 1987.
178. Shih TM, Rowland TC, McDonough JH. Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine. J Pharmacol Exp Ther 2007;320:154-161.
179. Dekundy A, Blaszczak P, Kaminski R, Turski WA. On the interactions between antimuscarinic atropine and NMDA receptor antagonists in anticholinesterase-treated mice. Arch Toxicol 2001;74:702-708.
180. Dekundy A, Kaminski RM, Turski WA. Dizocilpine improves beneficial effects of cholinergic antagonists in anticholinesterase-treated mice. Toxicol Sci 2003;72:289-295.
181. Dekundy A, Kaminski RM, Zielinska E, Turski WA. NMDA antagonists exert distinct effects in experimental organophosphate or carbamate poisoning in mice. Toxicol Appl Pharmacol 2007;219:114-121.
182. McDonough JH Jr., Shih TM. A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs. Pharmacol Biochem Behav 1995;51:249-253.
183. Ballough GPH, Newmark J, Levine ES, Filbert MG. Neuroprotection as a Treatment for Nerve Agent Survivors (Chapter 6). Medical aspects of chemical warfare Washington DC: U.S. Army Medical Department, Borden Institute, 2008; 219-242.
184. Wasterlain CG, Baldwin R, Naylor DE, Thompson KW, Suchomelova L, Niquet J. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia 2011;52(Suppl 8):70-71.
185. Fidecka S, Pirogowicz E. Lack of interaction between the behavioral effects of ketamine and benzodiazepines in mice. Pol J Pharmacol 2002;54:111-117.
186. Handa F, Tanaka M, Nishikawa T, Toyooka H. Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: a randomized, double-blind, placebo-controlled study. J Clin Anesth 2000;12:19-24.
187. Halonen T, Kotti T, Tuunanen J, Toppinen A, Miettinen R, Riekkinen PJ. Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. Brain Res 1995;693:217-224.
188. McLean MJ, Gupta RC, Dettbarn WD, Wamil AW. Prophylactic and therapeutic efficacy of memantine against seizures produced by soman in the rat. Toxicol Appl Pharmacol 1992;112:95-103.
189. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006;6:61-67.
190. Cakil D, Yildirim M, Ayyildiz M, Agar E. The effect of co-administration of the NMDA blocker with agonist and antagonist of CB1-receptor on penicillin-induced epileptiform activity in rats. Epilepsy Res 2011;93:128-137.
191. Lallement G, Pernot Marino I, Foquin Tarricone A, et al. Coadministration of atropine, NBQX and TCP against soman-induced seizures. NeuroReport 1994;5:1113-1117.
192. Lallement G, Pernot Marino I, Foquin Tarricone A, et al. Antiepileptic effects of NBQX against soman-induced seizures. NeuroReport 1994;5:425-428.
193. Pitkanen A, Mathiesen C, Ronn LC, Moller A, Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 2007;74:45-54.
194. Langer M, Brandt C, Zellinger C, Loscher W. Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology 2011;61:1033-1047.
195. Gigler G, Moricz K, Agoston M, et al. Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models. Br J Pharmacol 2007;152:151-160.
196. Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia 2010;51:108-117.
197. Howes JF, Bell C. Talampanel. Neurotherapeutics 2007;4:126-129.
198. Hottinger A, Sutter R, Marsch S, Ruegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs 2012;26:761-772.
199. Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF. The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther 2011;336:303-312.
200. Tang FR, Chen PM, Tang YC, Tsai MC, Lee WL. Two-methyl-6-phenylethynyl-pyridine (MPEP), a metabotropic glutamate receptor 5 antagonist, with low doses of MK801 and diazepam: a novel approach for controlling status epilepticus. Neuropharmacology 2007;53:821-831.
201. Carpentier P, Foquin A, Lallement G, Dorandeu F. Flunarizine: a possible adjuvant medication for soman poisoning. Drug Chem Toxicol 2004;27:213-231.
202. Stuiver BT, Douma BR, Bakker R, Nyakas C, Luiten PG. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration 1996;5:153-159.
203. Morales-Garcia JA, Luna-Medina R, Martinez A, Santos A, Perez-Castillo A. Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats. J Neurosci Res 2009;87:3687-3696.
204. Deshpande LS, Carter DS, Blair RE, DeLorenzo RJ. Development of a prolonged calcium plateau in hippocampal neurons in rats surviving status epilepticus induced by the organophosphate diisopropylfluorophosphate. Toxicol Sci 2010;116:623-631.
205. Nagarkatti N, Deshpande LS, DeLorenzo RJ. Development of the calcium plateau following status epilepticus: role of calcium in epileptogenesis. Expert Rev Neurother 2009;9:813-824.
206. Ingram EA, Toyoda I, Wen X, Buckmaster PS. Prolonged infusion of inhibitors of calcineurin or L-type calcium channels does not block mossy fiber sprouting in a model of temporal lobe epilepsy. Epilepsia 2009;50:56-64.
207. Schmitt FC, Dehnicke C, Merschhemke M, Meencke HJ. Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy Behav 2010;17:565-568.
208. Martinez Y, N'Gouemo P. Blockade of the sodium calcium exchanger exhibits anticonvulsant activity in a pilocarpine model of acute seizures in rats. Brain Res 2010;1366:211-216.
209. Amitai G, Adani R, Fishbein E, Meshulam H, Laish I, Dachir S. Bifunctional compounds eliciting anti-inflammatory and anti-cholinesterase activity as potential treatment of nerve and blister chemical agents poisoning. J Appl Toxicol 2006;26:81-87.
210. Ma L, Cui XL, Wang Y, et al. Aspirin attenuates spontaneous recurrent seizures and inhibits hippocampal neuronal loss, mossy fiber sprouting and aberrant neurogenesis following pilocarpine-induced status epilepticus in rats. Brain Res 2012;1469:103-113.
211. Gao F, Liu Y, Li X, Wang Y, Wei D, Jiang W. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol Biochem Behav 2012;103:187-196.
212. Fitzal S. [Ketamine and neuroprotection. Clinical outlook]. Anaesthesist 1997;46(Suppl 1):S65-S70.
213. Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury? Anesth Analg 2005;101:524-534.
214. Sehdev RS, Symmons DA, Kindl K. Ketamine for rapid sequence induction in patients with head injury in the emergency department. Emerg Med Australas 2006;18:37-44.
215. Chang L, Raty S, Ortiz J, Bailard N, Mathew S. The Emerging use of Ketamine for Anesthesia and Sedation in Traumatic Brain Injuries. CNS Neurosci Ther 2013; 19:390-395.
216. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991;254:1515-1518.
217. Fix AS, Horn JW, Wightman KA, et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 1993;123:204-215.
218. Fix AS, Ross JF, Stitzel SR, Switzer RC. Integrated evaluation of central nervous system lesions: Stains for neurons, astrocytes, and microglia reveal the spatial and temporal features of MK-801-induced neuronal necrosis in the rat cerebral cortex. Toxicol Pathol 1996;24:291-304.
219. Wang C, Liu F, Patterson T, Paule M, Slikker W Jr. Preclinical Assessment of Ketamine. CNS Neurosci Ther 2013; 19:448-453.
220. Jevtovic-Todorovic V, Benshoff N, Olney JW. Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. Br J Pharmacol 2000;130:1692-1698.
221. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW. A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Res 2001;895:264-267.
222. Kocsis B, Brown R, McCarley R, Hajos M. Impact of ketamine on neuronal network dynamics, translational modeling of schizophrenia-relevant deficits. CNS Neurosci Ther 2013; 19:437-447.
223. Winters WD. Epilepsy or anesthesia with ketamine. Anesthesiology 1972;36:309-312.
224. Kayama Y, Iwama K. The EEG, evoked potentials, and single-unit activity during ketamine anesthesia in cats. Anesthesiology 1972;36:316-328.
225. Bennett DR, Madsen JA, Jordan WS, Wiser WC. Ketamine anesthesia in brain-damaged epileptics. Electroencephalographic and clinical observations. Neurology 1973;23:449-460.
226. Ferrer-Allado T, Brechner VL, Dymond A, Cozen H, Crandall P. Ketamine-induced electroconvulsive phenomena in the human limbic and thalamic regions. Anesthesiology 1973;38:333-344.
227. Turitto P, Fiume-Garelli F, Pagnoni B. [Ketamine and epilepsy. Case report]. Minerva Anestesiol 1974;40:163-164.
228. Thompson GE. Ketamine-induced convulsions. Anesthesiology 1972;37:662-663.
229. De Vore GR, McQueen JK, Woodbury DM. Ketamine hydrochloride and its effect on a chronic cobalt epileptic cortical focus. Epilepsia 1976;17:111-117.
230. Kayama Y. Ketamine and e.e.g. seizure waves: interaction with anti-epileptic drugs. Br J Anaesth 1982;54:879-883.
231. Black JA, Golden GT, Fariello RG. Ketamine activation of experimental corticoreticular epilepsy. Neurology 1980;30:315-318.
232. Burmeister-Rother R, Streatfeild KA, Yoo MC. Convulsions following ketamine and atropine. Anaesthesia 1993;48:82.
233. Celesia GG, Chen RC, Bamforth BJ. Effects of ketamine in epilepsy. Neurology 1975;25:169-172.
234. Corssen G, Little SC, Tavakoli M. Ketamine and epilepsy. Anesth Analg 1974;53:319-335.
235. Voss LJ, Sleigh JW, Barnard JP, Kirsch HE. The howling cortex: seizures and general anesthetic drugs. Anesth Analg 2008;107:1689-1703.
236. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol 2006;13:445-450.
237. Rosenow F, Arzimanoglou A, Baulac M. Recent developments in treatment of status epilepticus: a review. Epileptic Disord 2002;4(Suppl 2):S41-S51.
238. Fisher MM. Use of ketamine hydrochloride in the treatment of convulsions. Anaesth Intensive Care 1974;2:266-268.
239. Davis RW, Tolstoshev GC. Ketamine-use in severe febrile convulsions. Med J Aust 1976;2:465-466.
240. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology 1998;51:1765-1766.
241. Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol 1997;9:269-272.
242. Mion G, Ruttimann M. [Ketamine from an anticonvulsant perspective]. Ann Fr Anesth Reanim 1997;16:1045-1046.
243. Bleck TP, Quigg M, Nathan BR, Smith TL, Kapur J. Electroencephalographic effects of ketamine treatment for refractory status epilepticus. Epilepsia 2002;43(Suppl 7):282.
244. Hsieh CY, Sung PS, Tsai JJ, Huang CW. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol 2010;33:165-167.
245. Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 2008;82:219-222.
246. Rosati A, L'Erario M, Ilvento L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology 2012;79:2355-2358.
247. Chau CM, Leung AK, Tan IK. Tetramine poisoning. Hong Kong Med J 2005;11:511-514.
248. Kramer AH. Early ketamine to treat refractory status epilepticus. Neurocrit Care 2012;16:299-305.
249. Mewasingh LD, Sekhara T, Aeby A, Christiaens FJC, Dan B. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure 2003;12:483-489.
250. Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure 2011;20:723-726.
251. Bhutta AT, Schmitz ML, Swearingen C, et al. Ketamine as a neuroprotective and anti-inflammatory agent in children undergoing surgery on cardiopulmonary bypass: a pilot randomized, double-blind, placebo-controlled trial. Pediatr Crit Care Med 2012;13:328-337.
252. Bhutta AT. Ketamine: a controversial drug for neonates. Semin Perinatol 2007;31:303-308.
253. Ubogu EE, Sagar SM, Lerner AJ, Maddux BN, Suarez JI, Werz MA. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav 2003;4:70-75.
254. Smith M. Anesthestic agents and status epilepticus. Epilepsia 2011;52(Suppl 8):42-44.
255. Schmutzhard E, Pfausler B. Complications of the management of status epilepticus in the intensive care unit. Epilepsia 2011;52(Suppl 8):39-41.
256. Hersack RA. Ketamine's psychological effects do not contraindicate its use based on a patient's occupation. Aviat Space Environ Med 1994;65:1041-1046.
257. Grathwohl KW, Black IH, Spinella PC, et al. Total intravenous anesthesia including ketamine versus volatile gas anesthesia for combat-related operative traumatic brain injury. Anesthesiology 2008;109:44-53.